Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical company, has announced the launch of TEVIMBRA® (tislelizumab) in India, marking its official entry into the immuno-oncology segment. The launch follows approval by the Central Drugs Standard Control Organization (CDSCO) and represents a major step forward in expanding access to innovative treatments for certain types of advanced cancers.
TEVIMBRA, a uniquely engineered anti-PD-1 monoclonal antibody, was originally developed by BeiGene, now known as BeOne Medicines, a global leader in oncology. In India, TEVIMBRA is approved for:
- First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and
- Second-line monotherapy for both NSCLC and esophageal squamous cell carcinoma (ESCC).
With this launch, Glenmark brings a globally validated immunotherapy option to Indian patients, many of whom are affected by NSCLC, the most prevalent type of lung cancer, accounting for over 80% of all lung cancer cases. Similarly, ESCC is the most common subtype of esophageal cancer in the country, further underlining the significance of this development.
“With the launch of TEVIMBRA, Glenmark is delivering on its commitment to transform cancer care in India by making globally benchmarked immunotherapies more accessible,” said Alok Malik, President and Business Head – India Formulations at Glenmark. “As cancer rates continue to rise, we are enabling oncologists to offer patients a treatment backed by strong science and robust global data. This marks a major inflection point in our journey toward building a world-class, inclusive, and innovative oncology portfolio.”
TEVIMBRA is already approved in 46 countries, including the United States, European Union, Australia, and China. It is designed to bind selectively to PD-1 receptors, restoring T-cell activity to help the immune system detect and fight tumors — all while minimizing off-target immune suppression. Its clinical efficacy and favorable safety profile have been demonstrated across multiple tumor types in a wide-ranging global clinical development program involving nearly 14,000 patients across 70 trials.
TEVIMBRA is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that targets the PD-1 protein. It is engineered to reduce binding to Fc-gamma (Fcγ) receptors on macrophages, thereby enhancing the body’s immune response against cancerous cells. As a cornerstone of BeOne Medicines’ solid tumor portfolio, TEVIMBRA has already benefited over 1.5 million patients globally.
